Cognitive Dysfunction in Chronic Kidney Disease Patients: Time to Prevent
DOI:
https://doi.org/10.71749/pkj.17Palavras-chave:
Cognitive Dysfunction, Renal DialysisResumo
Mild cognitive impairment (MCI) is a neurocognitive deterioration of at least one of the following six cognitive domains in humans: complex attention, executive function, learning and memory, language, perceptual‐motor, and social cognition. Patients with chronic kidney disease are at an increased risk of developing this disorder, with serious implications for the patient, family, and society. In this article, we aim to increase awareness of the disorder and summarize the existing evidence on the topic.Downloads
Referências
Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421‐42.
Pépin M, Ferreira AC, Arici M, Bachman M, Barbieri M, Bumblyte IA, et al. Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. Nephrol Dial Transplant 2021;37:ii23‐ii32. doi: 10.1093/ndt/gfab262.
Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta‐analysis. Am J Nephrol. 2012;35:474‐82. doi: 10.1159/000338135.
Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, et al. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc. 2010;58:338‐45. doi: 10.1111/j.1532‐5415.2009.02670.x.
Drew DA, Weiner DE, Sarnak MJ. Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. Am J Kidney Dis. 2019;74:782‐90. doi: 10.1053/j.ajkd.2019.05.017.
Viggiano D, Wagner CA, Martino G, Nedergaard M, Zoccali C, Unwin R, et al. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol. 2020;16:452‐69. doi: 10.1038/s41581‐020‐0266‐9.
Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, et al. Cognitive impairment in hemodialysis patients is common. Neurology. 2006;67:216‐23. doi: 10.1212/01. wnl.0000225182.15532.40.
van Zwieten A, Wong G, Ruospo M, Palmer SC, Teixeira‐Pinto A, Barulli MR, et al. Associations of Cognitive Function and Education Level With All‐Cause Mortality in Adults on Hemodialysis: Findings From the COGNITIVE‐HD Study. Am J Kidney Dis. 2019;74:452‐62. doi: 10.1053/j.ajkd.2019.03.424.
Viggiano D, Wagner CA, Martino G, Nedergaard M, Zoccali C, Unwin R, et al. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol. 2020;16:452‐69. doi: 10.1038/s41581‐020‐0266‐9.
Miglinas M, Cesniene U, Janusaite MM, Vinikovas A. Cerebrovascular disease and cognition in chronic kidney disease patients. Front Cardiovasc Med. 2020;7:96.
Weiner DE, Scott TM, Giang LM, Agganis BT, Sorensen EP, Tighiouart H, et al. Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis. 2011;58:773‐81. doi: 10.1053/j.ajkd.2011.03.034.
Cukierman‐Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes‐memory in diabetes (ACCORD‐MIND) trial. Diabetes Care. 2009;32:221‐6.
SPRINT MIND Investigators for the SPRINT Research Group; William‐ son JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321:553‐61. doi: 10.1001/ jama.2018.21442.
Shah SV, Shukla AM, Bose C, Basnakian AG, Rajapurkar M. Recent advances in understanding the pathogenesis of atherosclerosis in CKD patients. J Ren Nutr. 2015;25:205‐8.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low‐Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497‐505. doi: 10.1056/ NEJMoa1912388.
Natale P, Ruospo M, Saglimbene VM, Palmer SC, Strippoli GF. Interventions for improving sleep quality in people with chronic kidney disease. Cochrane Database Syst Rev. 2019;5:Cd012625. doi: 10.1002/14651858.CD012625.pub2.
Ferreira AC, Ferreira A. Renal Osteodystrophy and Bone Biopsy. Nephrology Self‐Assessment Program. 2023;22:40‐6.[accessed Jan 2023] Available from: https://nephsap.org/
McGrath ER, Himali JJ, Levy D, Conner SC, Pase MP, Abraham CR, et al. Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PLoS One. 2019;14:e0213321. doi: 10.1371/journal.pone.0213321.
Kuriyama N, Ozaki E, Mizuno T, Ihara M, Mizuno S, Koyama T, et al. Association between α‐Klotho and Deep White Matter Lesions in the Brain: A Pilot Case Control Study Using Brain MRI. J Alzheimers Dis. 2018;61:145‐55. doi: 10.3233/JAD‐170466.
Liabeuf S, Pepin M, Franssen CF, Viggiano D, Carriazo S, Gansevoort RT, et al. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrol Dial Transplant. 2021;37:ii33‐ii44. doi: 10.1093/ndt/gfab223.
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934‐43. doi: 10.1046/j.1523‐1755.2003.00924.x.
Farinha A, Robalo Nunes A, Mairos J, Fonseca C. Anemia da Doença Renal Crónica: O Estado da Arte. Acta Med Port. 2022;35:758‐64. doi: 10.20344/amp.17284.
Naseralallah L, Khatib M, Al‐Khulaifi A, Danjuma M. Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta‐analysis. Front Pharmacol. 2023;14:1122898. doi: 10.3389/fphar.2023.1122898.
Adjeroh L, Brothers T, Shawwa K, Ikram M, Al‐Mamun MA. The association between polypharmacy and health‐related quality of life among non‐dialysis chronic kidney disease patients. PLoS One. 2023;18:e0293912. doi: 10.1371/journal.pone.0293912.
van Oosten MJ, Koning D, Logtenberg SJ, Leegte MJ, Bilo HJ, Hemmelder MH, et al. Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population. Clin Kidney J. 2022;15:778‐85. doi: 10.1093/ckj/ sfab242.
Hafez G, Malyszko J, Golenia A, Klimkowicz‐Mrowiec A, Ferreira AC, Arıcı M, et al. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. Clin Kidney J. 2023;16:2378‐92. doi: 10.1093/ckj/sfad239.
Pépin M, Klimkowicz‐Mrowiec A, Godefroy O, Delgado P, Carriazo S, Ferreira AC, et al. Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment. Eur J Neurol. 2023;30:2899‐911. doi: 10.1111/ene.15928. E
Neumann D, Mau W, Wienke A, Girndt M. Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one‐year course. Kidney Int. 2018;93:430‐8.
Findlay MD, Dawson J, Dickie DA, Forbes KP, McGlynn D, Quinn T, et al. Investigating the Relationship between Cerebral Blood Flow and Cognitive Function in Hemodialysis Patients. J Am Soc Nephrol. 2019;30:147‐58. doi: 10.1681/ASN.2018050462.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111‐88. doi: 10.1093/eurheartj/ehz455.
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953‐2041. doi: 10.1097/ HJH.0000000000002026.
Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874‐2071. doi: 10.1097/ HJH.0000000000003480.
SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Stan‐ dard Blood‐Pressure Control. N Engl J Med. 2015;373:2103‐16. doi: 10.1056/NEJMoa1511939.
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:559‐69. doi: 10.1016/j.kint.2020.10.026.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1‐S87. doi: 10.1016/j.kint.2020.11.003.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes‐2023. Diabetes Care. 2023;46:S49‐s67. doi: 10.2337/dc23‐S004.
Rossing P, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102:990‐ ‐9. doi: 10.1016/j.kint.2022.06.013.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes‐2023. Diabetes Care. 2023;46:S140‐s57. doi: 10.2337/dc23‐S009.
Mathur A, Ahn JB, Sutton W, Chu NM, Gross AL, Segev DL,et al. Secondary hyperparathyroidism (CKD‐MBD) treatment and the risk of dementia. Nephrol Dial Transplant. 2022;37:2111‐8. doi: 10.1093/ ndt/gfac167.
Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta‐analysis. Neurology. 2012;79:1397‐405. doi: 10.1212/ WNL.0b013e31826c197f.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085‐98.
Iyalomhe O, Swierczek S, Enwerem N, Chen Y, Adedeji MO, Allard J, et al. The Role of Hypoxia‐Inducible Factor 1 in Mild Cognitive Impairment. Cell Mol Neurobiol. 2017;37:969‐77. doi: 10.1007/ s10571‐016‐0440‐6.
Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, et al. Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor. Clin Kidney J. 2023;16:2365‐77. doi: 10.1093/ckj/sfad241.
Eldehni MT, Odudu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol. 2015;26:957‐65. doi: 10.1681/ASN.2013101086.
Mustafa RA, Bdair F, Akl EA, Garg AX, Thiessen‐Philbrook H, Salameh H, et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta‐analysis. Clin J Am Soc Nephrol. 2016;11:442‐57. doi: 10.2215/CJN.04580415.
Downloads
Publicado
Edição
Secção
Licença
Direitos de Autor (c) 2024 Ana Carina Ferreira (Author)
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial 4.0.
